Pfizer Inc 0Q1N
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0Q1N is a good fit for your portfolio.
News
-
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
-
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
-
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk
-
How a Biden-Trump rematch can keep healthcare ETFs afloat this election year
-
BioNTech's stock sinks after earnings miss, as inventory writedowns weigh
-
Repeat & Correct: Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale — Update
-
Pfizer to Cut Stake in Haleon — Update
-
Pfizer to Cut Stake in Haleon to 24%
Trading Information
- Previous Close Price
- $25.55
- Day Range
- $25.21–25.50
- 52-Week Range
- $25.21–41.20
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $144.11 Bil
- Volume/Avg
- 37,339 / 373,513
Key Statistics
- Price/Earnings (Normalized)
- 14.19
- Price/Sales
- 2.52
- Dividend Yield (Trailing)
- 6.46%
- Dividend Yield (Forward)
- 6.58%
- Total Yield
- 6.46%
Company Profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 88,000
- Website
- https://www.pfizer.com
Competitors
Valuation
|
Metric
|
0Q1N
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.19 | 84.66 | 10.61 |
Price/Book Value | 1.66 | 8.56 | 4.78 |
Price/Sales | 2.52 | 5.38 | 2.23 |
Price/Cash Flow | 13.55 | 21.27 | 10.63 |
Price/Earnings
0Q1N
MRK
GSK
Financial Strength
|
Metric
|
0Q1N
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 0.58 | 0.68 | 0.59 |
Current Ratio | 0.91 | 1.25 | 0.88 |
Interest Coverage | 0.74 | 2.33 | 9.30 |
Quick Ratio
0Q1N
MRK
GSK
Profitability
|
Metric
|
0Q1N
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 4.98% | 3.59% | 10.54% |
Return on Equity (Normalized) | 10.90% | 9.12% | 50.48% |
Return on Invested Capital (Normalized) | 7.28% | 5.88% | 21.33% |
Return on Assets
0Q1N
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Nyzhrqwkx | Vzdf | $689.2 Bil | |
JNJ
| Johnson & Johnson | Vqsmbsqqj | Msgfp | $353.8 Bil | |
MRK
| Merck & Co Inc | Chpllws | Hzc | $321.5 Bil | |
ABBV
| AbbVie Inc | Cflplpz | Clyr | $296.2 Bil | |
AZN
| AstraZeneca PLC ADR | Xbbtgvpcn | Tzhm | $219.1 Bil | |
NVS
| Novartis AG ADR | Ydknrxqqg | Rqms | $200.8 Bil | |
RHHBY
| Roche Holding AG ADR | Pvfwpryvtk | Hcvs | $196.3 Bil | |
AMGN
| Amgen Inc | Rdckssmts | Mpwwc | $144.5 Bil | |
PFE
| Pfizer Inc | Ykzprhyx | Mdgy | $143.0 Bil | |
SNY
| Sanofi SA ADR | Skblfmnq | Ttwg | $117.2 Bil |